DexCom, Inc. (NASDAQ:DXCM) is Fisher Funds Management LTD's 10th Largest Position

Fisher Funds Management LTD increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 32.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,647,333 shares of the medical device company's stock after buying an additional 405,612 shares during the period. DexCom comprises about 2.7% of Fisher Funds Management LTD's portfolio, making the stock its 10th biggest position. Fisher Funds Management LTD owned 0.42% of DexCom worth $112,496,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Private Trust Co. NA raised its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Golden State Wealth Management LLC increased its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $82.73 on Friday. The company has a 50-day simple moving average of $83.03 and a 200-day simple moving average of $79.76. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The company has a market cap of $32.44 billion, a PE ratio of 61.74, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The firm's revenue was up 12.5% on a year-over-year basis. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director directly owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the transaction, the executive vice president directly owned 95,102 shares in the company, valued at $7,874,445.60. This represents a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock worth $2,281,732 over the last 90 days. Corporate insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research reports. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Truist Financial began coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price objective for the company. Finally, Wall Street Zen downgraded DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.